EPZM Epizyme, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

EPZM [NASD]

Epizyme, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-2.03	Insider Own	0.50%	Shs Outstand	99.62M	Perf Week	-4.17%
Market Cap	1.53B	Forward P/E	-	EPS next Y	-2.09	Insider Trans	-17.26%	Shs Float	79.12M	Perf Month	-17.16%
Income	-191.90M	PEG	-	EPS next Q	-0.61	Inst Own	95.90%	Short Float	10.10%	Perf Quarter	-14.16%
Sales	17.30M	P/S	88.51	EPS this Y	-12.00%	Inst Trans	1.05%	Short Ratio	7.28	Perf Half Y	-37.72%
Book/sh	3.05	P/B	4.97	EPS next Y	12.60%	ROA	-48.50%	Target Price	-	Perf Year	11.96%
Cash/sh	3.73	P/C	4.07	EPS next 5Y	38.00%	ROE	-67.20%	52W Range	9.73 - 27.82	Perf YTD	-38.37%
Dividend	-	P/FCF	-	EPS past 5Y	-3.00%	ROI	-53.70%	52W High	-45.51%	Beta	2.11
Dividend %	-	Quick Ratio	14.70	Sales past 5Y	-10.50%	Gross Margin	96.40%	52W Low	55.73%	ATR	1.13
Employees	203	Current Ratio	14.80	Sales Q/Q	-82.30%	Oper. Margin	-	RSI (14)	37.10	Volatility	4.75% 7.78%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-30.60%	Profit Margin	-	Rel Volume	0.79	Prev Close	15.17
Shortable	Yes	LT Debt/Eq	0.20	Earnings	May 04 BMO	Payout	-	Avg Volume	1.10M	Price	15.16
Recom	1.90	SMA20	-11.92%	SMA50	-13.45%	SMA200	-14.07%	Volume	866,607	Change	-0.07%

Apr-01-20

Downgrade

Oppenheimer

Outperform → Perform

Mar-04-20

Initiated

Barclays

Overweight

$33

Feb-25-20

Reiterated

H.C. Wainwright

Buy

$25 → $36

Jan-24-20

Downgrade

SVB Leerink

Outperform → Mkt Perform

Dec-06-19

Upgrade

Morgan Stanley

Equal-Weight → Overweight

May-30-19

Resumed

Citigroup

Buy

Jan-07-19

Upgrade

Leerink Partners

Mkt Perform → Outperform

Sep-07-18

Resumed

Morgan Stanley

Equal-Weight

Jul-03-18

Downgrade

Leerink Partners

Outperform → Mkt Perform

Jan-24-18

Resumed

Jefferies

Buy

$25

Jan-10-18

Initiated

Morgan Stanley

Overweight

$20

Nov-02-17

Downgrade

RBC Capital Mkts

Outperform → Sector Perform

$20 → $16

Sep-20-17

Initiated

Jefferies

Buy

$23

May-10-17

Resumed

RBC Capital Mkts

Outperform

$19 → $20

Apr-13-17

Initiated

Oppenheimer

Outperform

May-10-16

Reiterated

Mizuho

Buy

$20 → $18

Apr-05-16

Initiated

Citigroup

Buy

$17

Mar-14-16

Upgrade

H.C. Wainwright

Neutral → Buy

$25

Mar-10-16

Reiterated

Wedbush

Outperform

$33 → $22

Mar-10-16

Reiterated

Mizuho

Buy

$26 → $20

Jun-28-20 09:31AM	Insider Buying: The Epizyme, Inc. (NASDAQ:EPZM) Independent Chairman Just Bought 49% More Shares Simply Wall St.
Jun-20-20 07:57AM	Stock market gives up early gains to end lower as Apple plans to re-close stores and W.H.O. says coronavirus has entered new and dangerous phase MarketWatch
Jun-19-20 10:19AM	Epizyme Gets FDA Nod for Tazverik sNDA in Follicular Lymphoma Zacks -7.92%
10:02AM	Epizyme's shares fall after receiving new FDA approval for cancer drug MarketWatch
09:41AM	Are Options Traders Betting on a Big Move in Epizyme (EPZM) Stock? Zacks
Jun-18-20 01:31PM	Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK (tazemetostat) for Relapsed/Refractory Follicular Lymphoma Business Wire
08:34AM	The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions Benzinga
Jun-17-20 01:56PM	Hedge Funds Arent Done Buying Epizyme Inc (EPZM) Insider Monkey
Jun-16-20 07:09AM	2 Top Cancer Treatment Stocks to Buy in June Motley Fool
Jun-03-20 11:30AM	Epizyme (EPZM) Down 4.4% Since Last Earnings Report: Can It Rebound? Zacks
May-26-20 12:55PM	Edited Transcript of EPZM earnings conference call or presentation 4-May-20 1:00pm GMT Thomson Reuters StreetEvents
May-14-20 09:22AM	Epizyme (EPZM): Strong Industry, Solid Earnings Estimate Revisions Zacks
May-13-20 05:12PM	Epizyme to Present Data from Tazemetostat Clinical Program during the 2020 ASCO Virtual Scientific Program Business Wire
May-07-20 10:51AM	Allogene's (ALLO) Q1 Loss Widens Y/Y, Pipeline Progresses Zacks
May-05-20 09:11AM	Epizyme's (EPZM) Q1 Earnings Beat Estimates, Revenues Miss Zacks +10.13%
May-04-20 07:00PM	Epizyme Inc (EPZM) Q1 2020 Earnings Call Transcript Motley Fool +5.33%
07:45AM	Epizyme (EPZM) Reports Q1 Loss, Misses Revenue Estimates Zacks
07:04AM	Epizyme: Q1 Earnings Insights Benzinga
06:30AM	Epizyme Reports Business Progress and First Quarter 2020 Financial Results Business Wire
Apr-27-20 12:32PM	Earnings Preview: Epizyme (EPZM) Q1 Earnings Expected to Decline Zacks
06:30AM	Epizyme Announces Date of First Quarter 2020 Financial Results Business Wire
Apr-26-20 10:02AM	Is Epizyme, Inc.'s (NASDAQ:EPZM) CEO Overpaid Relative To Its Peers? Simply Wall St.
Apr-19-20 07:02AM	3 Top Biotech Stocks with FDA Approvals on the Horizon TipRanks
Apr-08-20 06:56PM	Is Epizyme Inc (EPZM) A Good Stock To Buy? Insider Monkey +11.83%
Mar-25-20 11:30AM	Epizyme (EPZM) Down 24.9% Since Last Earnings Report: Can It Rebound? Zacks -6.01%
Mar-20-20 06:30AM	Epizyme Appoints Jeffery Kutok, M.D., Ph.D., as Chief Scientific Officer Business Wire -6.55%
Mar-06-20 03:41AM	Edited Transcript of EPZM earnings conference call or presentation 24-Feb-20 1:30pm GMT Thomson Reuters StreetEvents
Feb-26-20 06:39AM	Epizyme, Inc. Annual Results Just Came Out: Here's What Analysts Are Forecasting For Next Year Simply Wall St.
Feb-25-20 12:09PM	Analysts: 3 Healthcare Stocks to Buy on Coronavirus Weakness TipRanks
09:38AM	Epizyme (EPZM) Q4 Earnings Miss Estimates, Revenues Beat Zacks
09:28AM	Are Options Traders Betting on a Big Move in Epizyme (EPZM) Stock? Zacks
05:17AM	Here are the Mass.-based firms hit hardest in Monday's stock rout American City Business Journals
Feb-24-20 07:45AM	Epizyme (EPZM) Reports Q4 Loss, Tops Revenue Estimates Zacks -13.02%
06:30AM	Epizyme, Inc. to Host Earnings Call ACCESSWIRE
06:30AM	Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results Business Wire
Feb-23-20 06:38PM	The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace Benzinga
Feb-20-20 08:42AM	Epizyme (EPZM) to Report Q4 Earnings: What's in the Cards? Zacks
Feb-19-20 09:21AM	Biotech Stock Roundup: INCY's Solid Q4 Results, EPZM & SGEN's Pipeline Updates Zacks
Feb-18-20 06:30AM	Epizyme Announces Date of Fourth Quarter and Full Year 2019 Results and Presentations at Upcoming Investor Conferences Business Wire
Feb-14-20 08:23AM	The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering Benzinga +9.13%
06:30AM	Epizyme Announces FDA Acceptance of New Drug Application for Filing with Priority Review for TAZVERIK (tazemetostat) for the Treatment of Follicular Lymphoma Business Wire
Feb-12-20 06:55AM	Investors Who Bought Epizyme (NASDAQ:EPZM) Shares Three Years Ago Are Now Up 81% Simply Wall St.
Feb-06-20 05:50PM	Epizyme (EPZM) Stock Sinks As Market Gains: What You Should Know Zacks
Feb-05-20 11:52AM	Steven Cohen Renews His Interest in Verastem GuruFocus.com
Jan-31-20 05:50PM	Epizyme (EPZM) Dips More Than Broader Markets: What You Should Know Zacks
Jan-29-20 09:59AM	Biotech Stock Roundup: EPZM Drug Gets FDA Nod, XLRN & HEPA Surge on Study Data Zacks
Jan-24-20 12:00PM	Are You Looking for a Top Momentum Pick? Why Epizyme (EPZM) is a Great Choice Zacks -16.17%
10:44AM	The Daily Biotech Pulse: FDA Nod For Epizyme, Sonoma Explores Options For Dermatology Business, Roche's Cancer Drug Flunks Study Benzinga
09:57AM	Epizyme Gets FDA Nod for Lead Drug in Epithelioid Sarcoma Zacks
05:52AM	Epizyme's Tazemetostat Drug For Epithelioid Sarcoma Gets Accelerated FDA Approval Benzinga
Jan-23-20 06:07PM	FDA approves local biotech's first rare-cancer drug American City Business Journals
05:16PM	Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma Business Wire
09:34AM	Axsome (AXSM) Completes Patient Randomization in TRD Study Zacks
09:04AM	Benzinga Pro's Top 5 Stocks To Watch For Thurs., Jan. 23, 2020: CODX, LUV, INTC, PAYC, EPZM Benzinga
Jan-22-20 11:30AM	Is Epizyme (EPZM) Outperforming Other Medical Stocks This Year? Zacks
10:00AM	Evoke Pharma's NDA Resubmission for Gimoti Gets FDA Acceptance Zacks
08:57AM	Is the Options Market Predicting a Spike in Epizyme (EPZM) Stock? Zacks
Jan-21-20 09:26AM	Puma Biotech's (PBYI) Breast Cancer Drug Nerlynx Aids Growth Zacks
Jan-20-20 02:04PM	The Week Ahead In Biotech: Focus On Epizyme, Merck Ahead Of PDUFA Dates, J&J To Kickstart Big Pharma Earnings Benzinga
09:32AM	Seattle Genetics Up More Than 40% in the Past Year: Here's Why Zacks
Jan-17-20 08:45AM	ACADIA (ACAD) Up More Than 100% in the Past Year: Here's Why Zacks
Jan-09-20 04:47PM	Applied Therapeutics Up on Positive Galactosemia Study Data Zacks
Jan-08-20 12:00PM	What Makes Epizyme (EPZM) a Strong Momentum Stock: Buy Now? Zacks
Jan-07-20 10:26AM	Blueprint Medicines Initiates Dosing in Liver Cancer Study Zacks
09:19AM	aTyr (LIFE) Surges on Collaboration Deal With Kyorin Pharma Zacks
Jan-06-20 06:30AM	Epizyme Announces Exercise of $50 Million Option with Royalty Pharma and Highlights Key 2020 Initiatives to Build Long-Term Value Business Wire
Dec-30-19 09:24AM	3 Healthcare Stocks With Huge FDA Decisions in January TipRanks
Dec-26-19 10:38AM	Epizyme (EPZM) Shares Soar on Lead Candidate's Progress Zacks
Dec-24-19 08:15AM	Will Epizyme Continue to Surge Higher? Zacks
Dec-23-19 10:18AM	Did Hedge Funds Drop The Ball On Epizyme Inc (EPZM) ? Insider Monkey
Dec-19-19 10:02AM	Epizyme Stock Up on Positive Advisory Votes for Tazemetostat Zacks
07:52AM	The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic Benzinga
Dec-18-19 05:27PM	Epizyme Submits New Drug Application to the U.S. FDA for Tazemetostat for the Treatment of Patients with Follicular Lymphoma Business Wire +10.47%
02:54PM	Epizyme's stock jumps on 11-0 vote from FDA adcomm MarketWatch
02:00PM	Epizyme Announces FDA Advisory Committee Votes Unanimously in Favor of Tazemetostat for the Treatment of Patients with Epithelioid Sarcoma Business Wire
12:50PM	FDA committee sets stage for Epizyme's first product approval American City Business Journals
11:10AM	FDA Votes Unanimously In Favor Of Epizyme's Tazemetostat Benzinga
08:46AM	Benzinga Pro's Top 5 Stocks To Watch For Wed., Dec. 18, 2019: UPS, MU, EPZM, SLDB, XXII Benzinga
07:05AM	Epizyme (EPZM) Trading of Stock Halted; Oncology Drug Advisory Committee to Review Tazemetostat at 8:00 a.m. ET Today Business Wire
Dec-17-19 09:11AM	5 Biotech Stocks That Have More Than Doubled This Year Zacks
07:25AM	Moving Average Crossover Alert: Epizyme Zacks
Dec-16-19 12:00PM	Epizyme (EPZM) Is Up 10.29% in One Week: What You Should Know Zacks
Dec-15-19 03:49PM	The Week Ahead In Biotech: Avadel, Epizyme In Focus In A Quiet Week Benzinga
Dec-12-19 11:56AM	The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech Zacks
Dec-11-19 09:04AM	5 Biotech Stocks Up More Than 100% This Year So Far Zacks
Dec-10-19 07:56AM	The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares Benzinga
Dec-07-19 10:05AM	Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma Business Wire
Dec-06-19 07:39AM	The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend Benzinga +19.08%
Dec-03-19 03:18PM	Epizyme Announces FDA Committee Review of Tazemetostat NDA Zacks
08:54AM	Implied Volatility Surging for Epizyme (EPZM) Stock Options Zacks
Dec-02-19 10:45AM	Epizyme Announces FDA Advisory Committee Meeting to Review Tazemetostat for the Treatment of Patients with Epithelioid Sarcoma Business Wire
Nov-28-19 10:00AM	Epizyme (EPZM) Is Up 6.9% in One Week: What You Should Know Zacks
Nov-26-19 09:38AM	Epizyme, Inc. (EPZM) Shares March Higher, Can It Continue? Zacks
Nov-07-19 06:08AM	These 36 Mass. firms made Deloitte's Technology Fast 500 American City Business Journals +6.59%
Nov-05-19 08:00AM	Royalty Pharma Announces Agreement to Purchase Future Royalties on Tazemetostat from Eisai for $330 Million and a $100 Million Initial Investment in Epizyme PR Newswire +18.46%
Nov-04-19 07:00AM	Epizyme Establishes Agreements for Up to $270 Million in Funding to Support Tazemetostat Commercialization and Pipeline Advancement Business Wire +5.15%
Oct-30-19 07:55AM	Epizyme (EPZM) Reports Q3 Loss, Tops Revenue Estimates Zacks +9.57%
06:30AM	Epizyme Announces Positive Pre-NDA Meeting for Tazemetostat for Follicular Lymphoma, Pipeline Updates and Third Quarter 2019 Results Business Wire
Oct-27-19 02:02PM	Hedge Funds Have Never Been This Bullish On Epizyme Inc (EPZM) Insider Monkey
Oct-15-19 08:37AM	We're Hopeful That Epizyme (NASDAQ:EPZM) Will Use Its Cash Wisely Simply Wall St.

Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors. It also develops tazemetostat in combination with R-CHOP that is in the Phase Ib/II clinical trials in elderly patients with DLBCL; and tazemetostat in combination with PD-L1 inhibitor, which is in the Phase Ib/II clinical trials for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer. In addition, the company is developing EZM8266, a G9a inhibitor that is in the Phase 1 study for the treatment of sickle cell disease; pinometostat, which is in the preclinical studies stage for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor that is in Phase II clinical trial for patients with solid tumors and NHL; and PRMT1 inhibitor, which is in the Phase 1 clinical trial. Epizyme, Inc. has collaboration agreements with Celgene Corporation; Genentech Inc.; Glaxo Group Limited; Boehringer Ingelheim International GmbH; Roche Molecular Systems, Inc.; Lymphoma Study Association; and Eisai Co. Ltd. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MOTT DAVID M	Director	Jun 26	Buy	16.03	62,019	994,165	82,601	Jun 26 07:12 PM
Beaulieu Joseph	Corporate Controller	Jun 26	Sale	16.15	317	5,120	4,838	Jun 30 09:04 AM
Bazemore Robert B	President & CEO	Jun 26	Sale	16.15	4,773	77,084	250,098	Jun 30 09:01 AM
Agarwal Shefali	Chief Medical Officer	Jun 26	Sale	16.15	1,805	29,151	78,611	Jun 30 08:56 AM
TOMBESI PAOLO	Chief Financial Officer	Jun 26	Sale	16.15	1,805	29,151	21,942	Jun 30 08:57 AM
Ros Matthew	See Remarks	Jun 26	Sale	16.15	2,728	44,057	57,507	Jun 30 08:54 AM
Ros Matthew	See Remarks	Jun 18	Option Exercise	9.47	112,003	1,060,669	120,449	Jun 22 07:31 PM
Bazemore Robert B	President & CEO	Jun 18	Option Exercise	8.98	10,000	89,800	264,371	Jun 22 07:36 PM
Bazemore Robert B	President & CEO	Jun 18	Sale	22.00	20,000	440,000	244,371	Jun 22 07:36 PM
Ros Matthew	See Remarks	Jun 18	Sale	21.24	112,003	2,378,444	51,798	Jun 22 07:31 PM
Beaulieu Joseph	Corporate Controller	Mar 25	Sale	15.28	212	3,239	4,961	Mar 26 09:11 PM
TOMBESI PAOLO	Chief Financial Officer	Mar 25	Sale	15.28	1,243	18,993	15,437	Mar 26 09:01 PM
Ros Matthew	See Remarks	Mar 25	Sale	15.28	1,243	18,993	51,798	Mar 26 09:01 PM
Agarwal Shefali	Chief Medical Officer	Mar 25	Sale	15.28	1,243	18,993	71,991	Mar 26 09:00 PM
Bazemore Robert B	President & CEO	Mar 25	Sale	15.28	3,285	50,195	254,371	Mar 26 09:00 PM
Allen Andrew R	Director	Mar 16	Option Exercise	9.33	12,500	116,625	12,500	Mar 18 04:30 PM
Beaulieu Joseph	Corporate Controller	Mar 03	Sale	22.18	996	22,091	3,617	Mar 05 06:52 PM
Agarwal Shefali	Chief Medical Officer	Jan 27	Sale	20.44	2,630	53,757	58,803	Jan 27 09:19 PM
Bazemore Robert B	President & CEO	Jan 27	Sale	20.44	6,074	124,153	84,668	Jan 27 09:17 PM
Agarwal Shefali	Chief Medical Officer	Jan 24	Sale	24.64	1,843	45,412	61,433	Jan 27 09:19 PM
Bazemore Robert B	President & CEO	Jan 24	Sale	24.62	3,002	73,909	90,742	Jan 27 09:17 PM
Ros Matthew	See Remarks	Jan 24	Sale	24.64	1,847	45,510	42,185	Jan 27 09:18 PM
Beaulieu Joseph	Corporate Controller	Jan 24	Sale	24.63	330	8,128	1,042	Jan 27 09:16 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience